Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Lung Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × AGN 194204 × Clear all
NCT01540071 2021-05-14

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Io Therapeutics

Phase 2 Completed
38 enrolled 11 charts
Genitourinary

Castration Resistant Prostate Cancer

NCT00964132 2009-09-03

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NuRx Pharmaceuticals, Inc.

Phase 2 Unknown
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡